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Pretreatment with EPO reduces the injury and dysfunction
caused by ischemia/reperfusion in the mouse kidney in vivo.
Background. Erythropoietin (EPO) is a potent stimulator
of erythroid progenitor cells and is known to be up-regulated
during states of hypoxia. Here we investigate the effects of renal
ischemia/reperfusion (I/R) on the degree of renal dysfunction
and injury with recombinant human EPO in mice when given as
either a 3-day pretreatment, or upon reperfusion of the kidney.
Methods. Mice were treated with EPO (1000 IU/kg/day sub-
cutaneously) for 3 days, or treated with EPO (1000 IU/kg sub-
cutaneously) upon reperfusion, and subsequently subjected to
bilateral renal artery occlusion (30 minutes) and reperfusion
(24 hours). At the end of experiments, the following indica-
tors and markers of renal injury and dysfunction were mea-
sured: plasma urea, creatinine, and aspartate aminotransferase
(AST), tissue myeloperoxidase (MPO) activity [for polymor-
phonuclear leukocyte (PMN) infiltration], and tissue malon-
aldehyde (MDA) levels (for tissue lipid peroxidation). Kidneys
were used for histologic evaluation of renal injury.
Results. EPO was able to significantly attenuate the renal
dysfunction and injury associated with I/R, as well as the tissue
injury. The increase in renal MPO activity and, hence, the degree
of PMN infiltration were also significantly reduced in EPO-
treated mice. In addition, lipid peroxidation as a result of renal
I/R injury was also attenuated in EPO-treated mice.
Conclusion. The protection afforded by the pretreatment
regime of EPO was greater than that of administering EPO
as a single bolus upon reperfusion. We propose that different
mechanisms underlie the protective effects seen with EPO when
given as either a daily pretreatment or as a single bolus, which
need to be further investigated.
Erythropoietin (EPO) is a glycoprotein hormone pro-
duced primarily by the adult kidney in the regulation
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of red blood cell production, exerting its hematopoi-
etic effects by stimulating the proliferation of committed
erythroid progenitor cells and their development into ma-
ture erythrocytes [1]. There are several recent reports
documenting that EPO reduces the injury caused by is-
chemia/reperfusion (I/R) of the brain [2, 3], eye [4], gut
[5], heart [6, 7], and kidney [8]. It is, however, less clear
whether EPO has to be given as a pretreatment or can be
given upon reperfusion of a previously ischemic tissue.
For instance, in the heart pretreatment of rats with EPO
(5000 IU/kg) at 24 hours and 0.5 hour prior to ischemia
reduces tissue injury and cardiac dysfunction, while the
acute administration of EPO (5000 IU/kg) on reperfusion
after coronary artery occlusion also reduces infarct size in
the rat [6]. Hitherto, there have been no attempts to com-
pare the efficacy of pretreatment of animals with EPO to
an acute administration of EPO either before the onset
of the ischemic insult or before the onset of reperfusion.
This is important, as the mechanisms underlying the pro-
tective effects of EPO in these two therapeutic regimens
may well be different. For instance, pretreatment of mice
with EPO (1000 IU/kg) for 3 days mobilizes endothelial
progenitor cells [9], and procedures which mobilize pro-
genitors have been shown to protect the heart [10] and
the hind limb [9] against ischemic injury.
Thus, this study was designed to compare the effects
of EPO on the renal dysfunction and injury caused by
I/R of the kidney of the mouse in vivo when given ei-
ther as a pretreatment (1000 IU/kg subcutaneously for
3 days) and when given in the same dose 5 minutes prior
to reperfusion of the previously ischemic kidney.
METHODS
Animals
Fifty-nine male C57BL/6J mice (Charles River, Milan,
Italy) weighing 25 to 30 g were used to assess the
role of recombinant human EPO (St. Bartholomew’s
983
984 Patel et al: EPO attenuates renal I/R injury in the mouse
Hospital Pharmacy) when administered acutely and
chronically in the pathogenesis of renal I/R in the mouse.
Mice were allowed access to food and water ad libitum
and were cared for in compliance with Italian regulations
on protection of animals used for experimental and other
scientific purposes (D.M. 116192), as well as with the
European Economic Community regulations (O.J. of
E.C. L358/1 12/18/1986).
Mice were divided into the following four groups in
experiments involving the acute administration of EPO:
(1) I/R group in which control mice underwent renal
ischemia for 30 minutes followed by reperfusion for
24 hours (N = 11); (2) I/R EPO prereperfusion group
included mice that were administered EPO (1000 IU/kg
subcutaneously bolus) 5 minutes prior to reperfusion
(N = 10); (3) sham group were sham-operated mice,
which were subjected to the surgical procedures de-
scribed above, but were not subjected to renal I/R (N =4);
and (4) sham EPO prereperfusion group were mice that
were treated identical to sham mice except for the admin-
istration of EPO (1000 IU/kg subcutaneously) 5 minutes
prior to sham reperfusion (N = 4).
In the above experiments, the route of administration
and dose of EPO were based on that of a previously re-
ported experiment in the mouse [9]. Mice, which did not
receive EPO, were administered 8 mL/kg saline (vehi-
cle for EPO) at equivalent time points (5 minutes prior
to reperfusion). In experiments involving the chronic ad-
ministration of EPO, mice were divided into the follow-
ing four groups: (1) I/R group included control mice,
which underwent renal ischemia for 30 minutes followed
by reperfusion for 24 hours (N = 6); (2) I/R EPO pre-
treatment group mice were administered EPO (1000
IU/kg/day subcutaneously) for 3 days prior to I/R (N =
6); (3) sham group were sham-operated mice, which were
subjected to the surgical procedures described above, but
were not subjected to renal I/R (N = 4); and (4) sham
EPO pretreatment-group were mice that were treated
identical to sham mice except for the administration of
EPO (1000 IU/kg/day subcutaneously) for 3 days prior to
sham I/R (N = 4).
Mice, which did not receive EPO, were administered
8 mL/kg/day saline (vehicle for EPO) at equivalent time
points (72, 48, and 24 hours before operation).
Renal I/R model
Mice were anesthetized using chloral hydrate (125 mg/
kg, intraperitoneally) and core body temperature main-
tained at 37◦C using a homoeothermic blanket. Mice were
maintained under anesthesia for the duration of ischemia
(i.e., 30 minutes). After performing a midline laparotomy,
mice from the I/R groups were subjected to bilateral re-
nal ischemia for 30 minutes, during which the renal arter-
ies and veins were occluded using microaneurysm clamps
[11]. The time of ischemia chosen was based on that found
to maximize reproducibility of renal functional impair-
ment, while minimizing mortality in these animals [11].
After the renal clamps were removed, the kidneys were
observed for a further 5 minutes to ensure reflow after
which 1 mL saline at 37◦C was injected into the abdomen
and the incision was sutured in two layers. Mice were
then returned to their cages where they were allowed
to recover from anesthesia and observed for 24 hours.
Sham-operated mice underwent identical surgical pro-
cedures to I/R mice except that microaneurysm clamps
were not applied.
Measurement of biochemical parameters
At the end of the reperfusion period, 1 mL blood sam-
ples were collected from anesthetized mice via cardiac
puncture. The samples were centrifuged (6000 rpm for
3 minutes) to separate plasma. All plasma samples were
analyzed for biochemical parameters within 24 hours af-
ter collection. Plasma urea and creatinine concentrations
were used as indicators of renal (glomerular) function
[11]. The rise in the plasma levels of aspartate aminotrans-
ferase (AST), an enzyme located in the proximal tubule,
was used as an indicator of reperfusion injury [11].
Histologic evaluation
Kidneys were removed from mice at the end of the ex-
perimental period after tying the renal pedicle, and cut
in a sagittal section into two halves. These tissue sam-
ples were fixed by immersion in 10% (wt/vol) formalde-
hyde in phosphate-buffered saline (PBS) (0.01 mol/L,
pH 7.4) at room temperature for 1 day. After dehydra-
tion using graded ethanol, the tissue was embedded in
Paraplast (Sherwood Medical, Mahwah, NJ, USA) and
cut in fine (8 lm) sections and mounted on glass slides.
Sections were then deparaffinized with xylene, counter-
stained with hematoxylin and eosin, and viewed under a
light microscope (Dialux 22) (Leitz, Milan, Italy).
Myeloperoxidase activity
Myeloperoxidase (MPO) activity in kidney samples
was determined as an index of polymorphonuclear
(PMN) leukocyte accumulation, as previously described
[11]. Kidneys were homogenized in a solution contain-
ing 0.5% hexa-decyl-trimethyl-ammonium bromide and
10 mmol/L 3-(N-morpholino)-propane-sulfonic acid dis-
solved in 80 mmol/L sodium phosphate buffer (pH 7), and
centrifuged for 30 minutes at 20,000g at 4◦C. An aliquot of
the supernatant was then allowed to react with a solution
of tetra-methyl-benzidine (16 mmol/L) and 1 mmol/L hy-
drogen peroxide. The rate of change in absorbance was
measured by a spectrophotometer at 650 nm. MPO ac-
tivity was defined as the quantity of enzyme degrading
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1 lmol peroxide/min at 37◦C and was expressed in units
per gram weight of wet tissue.
Malondialdehyde measurement
Malondialdehyde (MDA) levels in kidney samples
were determined as an indicator of lipid peroxidation, as
previously described [11]. Tissues were homogenized in
a 1.15% KCl solution. An aliquot of the homogenate was
added to a reaction mixture containing 200 lL of 8.1%
sodium dodecyl sulfate (SDS), 1500 lL of 20% acetic
acid (pH 3.5), 1500 lL of 0.8% thiobarbituric acid, and
700 lL of distilled water. The mixture was then boiled
for 1 hour at 95◦C and centrifuged at 3000g for 10 min-
utes. The absorbency of the supernatant was measured
by spectrophotometry at 550 nm.
Materials
Unless otherwise stated, all compounds used in this
study were purchased from Sigma-Aldrich Company Ltd.
(Milan, Italy). All solutions used in vivo were prepared
using non-pyrogenic saline [0.9% (wt/vol) NaCl] (Baxter
Healthcare Ltd., Thetford, Norfolk, UK).
Statistical analysis
All values described in the text and figures are ex-
pressed as mean ± standard error of the mean (SEM) for
N observations. Each data point represents biochemical
measurements obtained from four to 13 separate animals.
For histologic scoring, each data point represents analy-
sis of kidneys taken from four to 13 individual animals.
One-way analysis of variance (ANOVA) with Dunnett’s
post test was performed using GraphPad Prism version
4.00 for Windows (GraphPad Software, San Diego, CA,
USA, www.graphpad.com) and a P value of less than 0.05
was considered to be significant.
RESULTS
Effect of EPO on renal dysfunction caused by I/R: Plasma
urea and creatinine
When compared to sham-operated mice, I/R caused a
significant increase in the plasma levels of urea and cre-
atinine in control mice (Fig. 1), suggesting a significant
degree of renal dysfunction. Administration of EPO, ei-
ther acutely (1000 IU/kg prior to reperfusion) (Fig. 1A
and B) or chronically (1000 IU/kg/day for 3 days prior
to I/R) (Fig. 1C and D), attenuated the renal dysfunction
caused by I/R in control mice. It should be noted that
the protection afforded by the chronic administration of
EPO was more pronounced.
Effect of EPO on renal dysfunction caused by I/R:
Plasma AST
When compared to sham-operated mice, I/R caused a
significant increase in the plasma levels of AST in control
mice, suggesting significant reperfusion injury (Fig. 2).
Administration of EPO, either acutely (1000 IU/kg prior
to reperfusion) (Fig. 2A) or chronically (1000 IU/kg/day
prior to I/R) (Fig. 2B), attenuated the renal injury caused
by I/R in control mice. It should be noted that the protec-
tion afforded by the chronic administration of EPO was
more pronounced.
Effect of EPO on renal injury caused by I/R:
Histologic assessment
When compared to sham-operated mice (Fig. 3A), his-
tological examination of kidneys obtained from control
mice subjected to I/R demonstrated a significant degree
of renal injury (Fig. 3B). Specifically, kidneys obtained
from these animals exhibited degeneration of tubular
structure, tubular dilatation, swelling and necrosis, lu-
minal congestion, and eosinophilia. In contrast, renal
sections obtained from mice treated with EPO acutely
(1000 IU/kg prior to reperfusion) (Fig. 3C) and
chronically (1000 IU/kg/day prior to I/R) (Fig. 3D)
demonstrated a marked reduction in the severity of these
histologic features of renal injury, when compared with
kidneys obtained from control mice subjected to I/R only
(Fig. 3B).
Effect of EPO on renal inflammation caused by I/R: MPO
activity and MDA levels
When compared to sham-operated mice, the kidneys
obtained from control mice subjected to I/R demon-
strated a significant increase in MPO activity (Fig. 4A
and C), suggesting increased PMN infiltration into renal
tissues. The increase in the tissue level of MPO seen in
mice administered EPO, either acutely (1000 IU/kg prior
to reperfusion) (Fig. 4A) or chronically (1000 IU/kg/day
prior to I/R) (Fig. 4C) was significantly smaller than those
seen in control mice subjected to I/R, which in the case of
chronic EPO treatment were similar to values obtained
from sham-operated mice. It should be noted that the
chronic administration of EPO reduced the MPO levels
to levels which were not different from those observed in
sham-operated animals.
When compared to sham-operated mice, the kidneys
obtained from control mice subjected to I/R demon-
strated a significant increase in MDA levels (Fig. 4B and
D), suggesting increased lipid peroxidation in renal tis-
sues. The increase in the tissue level of MDA seen in
mice administered EPO, either acutely (1000 IU/kg prior
to reperfusion) (Fig. 4B) or chronically (1000 IU/kg/day
prior to I/R) (Fig. 4D) was significantly smaller than those
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D Fig. 1. Effect of erythropoietin (EPO) on
renal function. Plasma urea (A) and creati-
nine levels (B) were measured, from mice
administered EPO prior to reperfusion, as
biochemical markers of renal dysfunction sub-
sequent to sham operation (Sham) (N =
4); Sham EPO prereperfusion (1000 IU/kg
prior to reperfusion) (N = 4); or renal is-
chemia/reperfusion (I/R) (N = 11); I/R EPO
prereperfusion (1000 IU/kg prior to reperfu-
sion) (N = 10). Plasma urea (C) and crea-
tinine levels (D) were measured, from mice
administered EPO as a 3-day pretreatment,
as biochemical markers of renal dysfunction
subsequent to sham operation (Sham) (N =
4); Sham EPO pretreatment (1000 IU/kg/day
prior to I/R) (N = 4); or renal I/R (N = 6);
I/R EPO pretreatment (1000 IU/kg/day prior
to I/R) (N = 6). Data represent mean ± SEM
for number of observations, ∗P < 0.05 vs. renal
I/R group.
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Fig. 2. Effect of erythropoietin (EPO) on
renal reperfusion-injury. Plasma aspartate
aminotransferase (AST) (A) levels were mea-
sured, from mice administered EPO prior to
reperfusion, as a biochemical marker of renal
injury subsequent to sham operation (Sham)
(N = 4); Sham EPO prereperfusion (1000
IU/kg prior to reperfusion) (N = 4); or renal
ischemia/reperfusion (I/R) (N = 11); I/R EPO
prereperfusion (1000 IU/kg prior to reperfu-
sion) (N = 10). Plasma AST (B) levels were
measured, from mice administered EPO as a
3-day pretreatment, as a biochemical marker
of renal injury subsequent to sham-operation
(Sham) (N = 4); Sham EPO pretreatment
(1000 IU/kg/day prior to I/R) (N = 4); or
renal I/R (N = 6); I/R EPO pretreatment
(1000 IU/kg/day prior to I/R) (N = 6). Data
represent mean ± SEM for number of obser-
vations, ∗P < 0.05 vs. renal I/R group.
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Fig. 3. Effect of erythropoietin (EPO) on re-
nal injury: Histologic examination. A renal
section taken from a sham-operated mouse
(A) is compared with that taken from a mouse
subjected to renal ischemia/reperfusion (I/R)
(B). A renal section taken from a mouse sub-
jected to renal I/R administered 1000 IU/kg
EPO prior to reperfusion (C) is represented.
Addtionally, a renal section taken from a
mouse subjected to renal I/R administered
1000 IU/kg/day EPO prior to I/R to is also rep-
resented (D) (hematoxylin and eosin, original
magnification ×150). Figures are representa-
tive of at least three experiments performed
on different days (N = 4 to 11 for all groups).
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D Fig. 4. Effect of erythropoietin (EPO) on re-
nal inflammation. Myeloperoxidase (MPO)
activity (A) and malonaldehyde (MDA) levels
(B) were measured from mice administered
EPO prior to reperfusion, subsequent to sham
operation (Sham) (N = 4); Sham EPO prior
to reperfusion (1000 IU/kg prior to reperfu-
sion) (N = 4); or renal ischemia/reperfusion
(I/R) (N = 11); I/R EPO prior to reperfu-
sion (1000 IU/kg prior to reperfusion) (N =
10). MPO activity (C) and MDA levels
(D) were measured from mice administered
EPO as a 3-day pretreatment, subsequent to
sham operation (Sham) (N = 4); Sham EPO
pretreatment (1000 IU/kg/day prior to I/R)
(N = 4) or renal I/R (N = 6); I/R EPO
pretreatment (1000 IU/kg/day prior to I/R)
(N = 6). Data represent mean ± SEM for
number of observations, ∗P < 0.05 vs. renal
I/R wild-type group.
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seen in control mice subjected to I/R. The reduction in
the degree of lipid peroxidation afforded by EPO was
similar when EPO was given as a pretreatment or given
upon reperfusion.
There were no differences in any of the above parame-
ters measured between sham-operated EPO (1000 IU/
kg)-treated mice, sham-operated EPO (1000 IU/kg/
day)-treated mice or sham-operated mice (see Figs. 1, 2,
and 4).
DISCUSSION
EPO, the critical hormone promoting the survival
and differentiation of erythroid progenitor cells, is cur-
rently being used in the therapy of patients with chronic
renal failure suffering from anemia [12]. Here we demon-
strate for the first time that EPO also reduces the re-
nal dysfunction and injury caused by bilateral occlusion
(30 minutes) and reperfusion (24 hours) in anesthetized
mice. Specifically, in mice subjected to renal I/R, EPO
(1000 IU/kg given 5 minutes prior to reperfusion) signif-
icantly attenuated the (1) renal dysfunction (increases in
plasma creatinine and urea); (2) reperfusion injury (in-
crease in plasma AST); (3) characteristic histologic signs
of marked tubular injury; (4) PMN accumulation (MPO
assay); and (5) lipid peroxidation (MDA assay). All this
data confirmed a well-known pattern of renal dysfunction
and injury caused by I/R of the kidney [13–15]. Moreover,
our findings are in agreement with the notion that renal
I/R causes both renal and tubular dysfunction [16], as well
as secondary inflammation [17].
We also report that the pretreatment of mice with EPO
(1000 IU/kg/day for 3 days) also reduced the renal in-
jury, dysfunction, and inflammation caused by bilateral
renal artery occlusion in the mouse. We have previously
demonstrated that EPO reduced both necrotic and apop-
totic cell death in vitro and reduced renal injury in a rat
model of I/R. Importantly, this study shows that EPO, in
contrast to other candidate therapies for acute renal fail-
ure, notably insulin-like growth factor-1 (IGF-1), is effec-
tive in different species [18]. Most notably, we discovered
that the degree of protection against injury, dysfunction,
and inflammation afforded by the pretreatment regimen
with EPO was greater than the one afforded by the acute
administration of EPO upon reperfusion. There are sev-
eral potential explanations for this finding.
First, one could argue that the pretreatment proto-
col has resulted in favorable systemic or renal hemody-
namic effects. However, although acute administration of
EPO (in the rat) had no effect on blood pressure, cortical
and pyramidal perfusion, the repetitive administration of
EPO for up to 1 week caused a small reduction in cortical
blood flow [19]. This would argue against hemodynamic
changes affecting preinsult glomerular filtration rate, but
might contribute to delayed pre-conditioning (discussed
below).
Second, as the half-life of EPO is ∼10 hours in the
rodent, it is possible and likely that the repetitive ad-
ministration of 1000 IU/kg subcutaneously per day for
3 days (pretreatment protocol) resulted in a higher
steady-state plasma concentration, when compared to
the peak concentration achieved from a single dose ad-
ministration prior to reperfusion (1000 IU/kg prior to
reperfusion).
Third, pretreatment of mice with EPO for 3 days
may well have resulted in the up-regulation of protec-
tive genes, including endothelial nitric oxide synthase
(eNOS), magnesium superoxide dismutase (Mn-SOD)
and heat shock protein 70 (HSP70), which in turn could
have contributed to the observed protective effect, mim-
icking the effects of delayed preconditioning. Delayed
ischemic preconditioning is protective in animal mod-
els of ischemic myocardial and brain injury, and is
mediated by the up-regulation of multiple factors, includ-
ing EPO, vascular endothelial growth factor and heme
oxygenase-1, which improve tissue performance in re-
sponse to metabolic stress under the control of the oxy-
gen sensor hypoxia-inducible factor-1a (HIF-1a). The
effects of delayed preconditioning were lost in HIF-
1a+/− mice [20]. The crucial role of the down stream ef-
fects of EPO production in delayed preconditioning of
brain injury has been demonstrated by the attenuation of
protection observed with the use of a soluble EPO recep-
tor [21], and in vitro, medium transfer from hypoxic and
glucose-starved astrocytes to untreated neurons induced
protection against hypoxia in neuronal cells, which was
attenuated strongly by the application of a soluble EPO
receptor and anti-EPO receptor antibodies [22]. In the
rat kidney, preconditioning with EPO 24 hours before
ischemia was associated with reduced injury, mediated
in part by the up-regulation of HSP70 and the antiapop-
totic protein Bcl-2 [23]. The main difference is that unlike
treatment at reperfusion, preconditioning with the pre-
treatment protocol enables increased protein synthesis
and not simply activation of existing proteins.
Fourth, the recent findings that bone marrow–derived
stem cells contribute to the regeneration of proximal
tubule epithelial cells following I/R injury [24] also cre-
ates an attractive hypothesis that the protection observed
with EPO pretreatment is partially due to an increase in
the mobilization and circulation of endothelial progen-
itor cells and possibly bone marrow–derived stem cells.
It has been shown in mice that EPO treatment caused
a significant increase in the percentage of proliferating
lin−/sca-1+ stem cells in the bone marrow and mobiliza-
tion of endothelial progenitor cells [9, 25].
There is evidence that the pretreatment protocol of
EPO used here results in enhanced levels of circulating
endothelial progenitor cells. Most notably, it has been
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suggested [9] that the increase in circulating endothelial
progenitor cells by EPO contributes to the beneficial ef-
fects of EPO in animal models of I/R. It is, however, not
known whether enhanced circulating levels of endothe-
lial cell progenitors protect the kidney against I/R injury
or improve recovery of renal function after an acute is-
chemic event.
CONCLUSION
Our data has demonstrated, for the first time, that re-
combinant EPO significantly reduces the renal injury and
dysfunction associated with I/R in the mouse. The de-
gree of protection was dependent on the timing of ad-
ministration of EPO, with pretreatment for 3 days prov-
ing to be more effective than a single treatment at the
time of reperfusion. Understanding the mechanisms of
signaling pathways that are involved in the protection of
the kidney from ischemic injury may lead to advances in
the clinical management of patients with syndromes of
acute ischemic injury, and our data support the use of
EPO in clinical trials in the treatment of ischemic renal
failure.
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